Introduction {#s1}
============

For many years, the skeletal system was regarded purely as a means for structural support and movement; however, abundant data have since been collected that reveal a complex bi-directional interaction between bone cells and surrounding bone marrow (BM) cells. BM is composed of a heterogeneous cell population including adipocytes, chondrocytes, endothelial cells, immune cells, fibroblasts, and two multipotent stem cell populations: mesenchymal stem cells (MSCs) and haematopoietic stem cells (HSCs). MSCs can differentiate into chondrocytes, bone marrow adipocytes (BMAs), and osteoblasts (bone-forming cells), while HSCs give rise to both the myeloid and lymphoid immune cell populations. The myeloid cell precursors are of particular interest as they can give rise to both innate monocyte/macrophage immune cells, but can also fuse and differentiate to form osteoclasts, the cells responsible for bone resorption.

BM cells are involved in activating and intensifying numerous signaling pathways that contribute to diseased states. The instigation of these signaling pathways can be coupled to the secretion of soluble factors by bone and stromal cells, alike. Such soluble factors include interleukin 6 (IL-6), insulin-like growth factor-1 (IGF-1), stromal cell-derived factor-1 (SDF-1), tumor necrosis factor alpha (TNF-α), interleukin-8 (IL-8), interleukin-17 (IL-17) and vascular endothelial growth factor (VEGF), which play roles in inflammation, immunosuppression, tumorigenesis, and osteolysis and thus contribute to many disease states. A number of these molecules activate NF-κB signaling, which is key in the BMM, as it binds to and activates important transcription factors and signaling cascades.

The NF-κB molecule associates with STAT3, which then induces the expression of wound healing and cancer gene products ([@B1]), such as anti-apoptotic proteins. Furthermore, STAT3 signaling results in the release of inflammatory molecules, such as IL-6 ([@B2]), SDF-1 ([@B3]), TNF-α ([@B4]), interleukin-1 (IL-1) and (IL-6) ([@B5]), which are all known to stimulate NF-κB signaling, thus creating a positive feedback loop and increased downstream inflammatory cytokine production ([@B2]). This vicious circle of NF-κB signaling can be detrimental to bone due to chronic inflammation and damage, yet it remains key in the maintenance of healthy bone, as it facilitates osteoclast differentiation and survival ([@B6]) and thus bone homeostasis.

Receptor activator of nuclear factor kappa-B ligand (RANKL) is a molecule expressed on osteoblasts which can facilitate the fusion of myeloid progenitors into osteoclasts ([@B7]). When RANKL binds to progenitor cells, it promotes NF-κB signaling, blockade of TNF receptor associated factor-3 (TRAF-3), promotion of NF-κB inducing kinase (NIK), and a consequential translocation of RelB and p52 (NF-κB2) into cell nuclei ([@B8]), which promotes signaling for osteoclastogenesis ([@B8]). MAPK pathways, particularly those involving p38, feed into this system, as they are both activated by NF-κB, but furthermore, are known to result in the production of RANKL. IL-1, for example, can stimulate RANKL via p38 in stromal cells thus promoting osteoclastogenesis ([@B9]). The extent of osteoclastogenesis is regulated by an equilibrium between RANKL and its inhibitor, osteoprotegerin (OPG).

The regulation of these bone signaling pathways is key in the limitation of bone disease. Inflammatory cytokines can disrupt ratios of RANKL:OPG and can result in excessive osteoclastogenesis. IL-6, is tied to excessive promotion of RANKL and inhibition of OPG and thus has been linked to bone osteolysis ([@B10]), osteoporosis ([@B11]), rheumatoid arthritis ([@B11]) and other bone-related pathologies. Osteolysis has further implications as it allows for the release of growth factors which promote the homing and survival of bone-metastatic cancers ([@B12]), such as prostate ([@B13]), breast ([@B14]) neuroblastoma ([@B15]), acute myeloid leukemia (AML) ([@B16]) and MM ([@B17], [@B18]).

MM is a blood cancer which epitomizes the crosstalk between the immune and bone systems. It is a commonly refractory, and thus recurrent, pathology characterized by uncontrollable clonal expansion of plasma cells. Myeloma cells grow in the BMM where they disrupt the delicate balance between bone growth and resorption through the secretion of factors that directly and indirectly promote osteoclasts and inhibit osteoblasts. This interaction between myeloma cells and the BMM, and the potential to activate dormant immune cells to kill myeloma cells in the BM, demonstrate exciting areas of osteoimmunology under scrutiny. It is the hope that a better understanding of the signals in the BM may allow for the identification of better targets and development of better combination therapies for MM and other bone disease. This review focuses on just one signaling pathway, IL-6, and its ability to promote both diseased and healthy states within the BMM. Since MM is strongly tied to IL-6, it will be used frequently as a disease example to emphasize the role of IL-6 in bone osteolysis, bone-metastatic cancer and general bone disease.

IL-6 and Bone Remodeling {#s2}
========================

Healthy bone is maintained by continuous bone resorption and regrowth, which is held at equilibrium through numerous signaling cascades ([@B19], [@B20]). Osteoclasts secrete acidic collagenases that break down matrices and form resorption pits. Osteoblasts line the border of mineralized bone and produce and deposit collagen, osteocalcin, and osteopontin to form an osteoid matrix. Osteoblasts then calcify osteoid through deposition of calcium phosphate, calcium carbonate and hydroxyapatite. Osteocytes, or other systemic signals, control the balance of bone resorption and formation. Osteocytes, the most abundant cell type in bone, are mechanosensing cells that produce signaling molecules in response to changes in pressure, sheer stress, or BMM chemical signals. Sclerostin is a signaling molecule that is synthesized and secreted by osteocytes, and acts as a WNT inhibitor causing inhibited osteoblast differentiation and supporting adipogenesis ([@B21]). Osteocytes also secrete Dentin-Matrix-acidic-Phosphoprotein-1(DMP-1), Matrix-Extracellular-Phospho-glycoprotein (MEPE), RANKL, Fibroblast-Growth-Factor-23 (FGF-23) and Phosphate-regulating-neutral-Endopeptidase-X-linked (PHEX), all of which play roles in regulating bone mineralisation, cell fate or phosphate homeostasis ([@B21], [@B22]).

Inflammatory cytokines, such as IL-6 and IL-11, can modulate skeletal homeostasis and osteoclast differentiation. When IL-6 binds receptors on pre-osteoclasts, they promote osteoclastogenesis ([@B23]), resulting in increased levels of bone resorption (Figure [1](#F1){ref-type="fig"}). Along with its direct roles on osteoclastogenesis, IL-6 also alters bone remodeling; when activated by IL-6, osteoblasts induce JAK/STAT3 pathways and ultimately secrete pro-osteoclast mediators, including RANKL, IL-1, parathyroid hormone related protein (PTHrP), and prostaglandin E2 (PGE2) ([@B12], [@B24]--[@B27]). PGE2 and PTHrP are particularly interesting factors as both, along with parathyroid hormone (PTH) and active vitamin D \[1,25(OH)2D3\], have been shown to stimulate IL-6 and RANKL production in osteoblasts within the BMM ([@B28], [@B29]). Thus, PGE2 and PTHrP reside both upstream and downstream of IL-6 signaling, facilitating a positive feedback loop that can exacerbate the detrimental pro-osteoclastic mechanisms seen in many diseased states. IL-6 can promote PTHrP secretion via TNF-α, which itself enhances osteoclastogenesis, bone loss and hypercalcaemia ([@B30]). The pathways that use osteoblastic mediation require the soluble IL-6 receptor (sIL-6R), as osteoblasts ordinarily express only low levels of the endogenous receptor ([@B12]). Soluble IL-6R forms as a result of cleavage or alternate splicing of IL-6R and is found in circulation in low numbers due to secretion from cells ([@B31]), commonly CD4 T cells ([@B32]). Therefore, it is necessary for IL-6 to meet and bind to sIL-6R within circulation, and then once bound, fuse with the osteoblastic membrane to trigger IL-6-inducible signaling pathways. Consequently, high levels of both IL-6 and sIL-6R are markers for osteolytic disorders, such as rheumatoid arthritis ([@B10]).

![Actions of IL-6 in the diseased bone marrow microenvironment. (A) Myeloma cells or other inflammatory triggers can induce osteoclast differentiation and osteolytic activity, which releases growth factors and IL-6 stored in the bone matrix (B). (C) Myeloma cells, or other inflammatory mediators, activate the release of IL-6 from osteoblasts (D); IL-6 then inhibits the activity of osteoblasts and induces their production of RANKL (E). (F,G) IL-6 from many sources, as well as RANKL from osteoblasts, induce pre-osteoclasts to differentiate into mature osteoclasts, which then resorb bone to induce greater release of stored growth factors, creating a vicious cycle. (H) Myeloma cells also alter bone marrow adipocytes to make a more supportive niche for tumor cells and to increase osteoclastic activity through IL-6 and other molecules.](fendo-09-00788-g0001){#F1}

IL-6 also exacerbates osteolysis through inhibition of osteoblast differentiation, further disrupting the balance of healthy bone turnover. Both IL-6 and sIL-6R can cause a decrease in osteoblastic differentiation by reducing expression of genes involved in osteoblastic differentiation including alkaline phosphatase (ALP), Runx2 and osteocalcin ([@B33]). IL-6/sIL-6R signaling can also reduce the ability of osteoblasts to mineralise bone (Figure [1](#F1){ref-type="fig"}). This was determined to be a result of MEK/ERK and PI3K/AKT2 pathways; inhibiting these pathways increased expression of Runx2 and other mature osteoblastic phenotypes ([@B33]). Similarly, c-Src (a proto-oncogenic tyrosine kinase) has been shown to activate STAT3 and stimulate IL-6 within immature osteoblasts ([@B34]). This stimulation can induce expression of insulin-like growth factor 5 (IGFP5)---a molecule thought to act in a paracrine fashion to inhibit osteoclastogenesis ([@B34]). Overall, IL-6 has been shown to have anti-osteogenic and pro-osteoclastic effects leading to a net inhibition of bone.

IL-6 and Non-Cancerous Bone Disease {#s3}
===================================

Regulation of IL-6 plays a crucial role in bone maintenance and remodeling. Commonly, when chronic injury and/or inflammation occurs, it instigates overexpression of IL-6 within the BMM resulting in pro-osteoclastic pathways, osteopenia, osteoporosis, and an increased fracture risk ([@B12]). In fact, diseases characterized by excessive bone loss commonly coincide with IL-6 and RANKL overproduction ([@B10]). Numerous signaling molecules interact with IL-6 to accelerate bone disease including PGE2/COX2, PTH, 1,25(OH)2D3, estrogen, and VEGF, as described below.

PGE2 results from metabolism of the fatty acid arachidonic acid via cyclooxygenase-2 (COX-2). Overexpression of COX-2 is driven by IL-6 signaling and results in increased production PGE2 ([@B35]). PGE2 interacts with G-coupled receptors EP1, EP2, and EP4, which activate tissue-specific downstream signaling pathways ([@B36]). Inflammatory conditions such as rheumatoid arthritis and osteoarthritis appear are tied PGE2-induced inflammation ([@B37]). Mast cells ([@B38]), Th17 cells ([@B39]) and dendrites ([@B40]) can all be stimulated by PGE2 via EP2 and EP4, resulting in the release of pro-inflammatory cytokines, e.g., IL-6 ([@B41]). PGE2 is also linked to osteoclastogenesis and breakdown of juxta-articular-bone and cartilage ([@B42]). PGE2 further disrupts bone homeostasis due to its ability to inhibit OPG secretion by osteoblasts ([@B27]). Use of anti-IL-6 antibodies in osteoblastic and monocyte/macrophage-like cell lines demonstrated increased OPG secretion through alleviation of PGE2-driven inhibition ([@B27]), thus concluding that PGE2 increases IL-6 signaling, driving osteoclastogenesis in part through OPG inhibition.

Similar to PGE2, PTH acts both upstream and downstream of IL-6 signaling. This hormone is expressed in response to hypocalcaemia and, once in circulation, it acts upon osteoblasts to both increase their activity and induce secretion of factors such as RANKL and IL-6 ([@B43]), which promote osteoclastic activity. PTH-induced bone loss can be inhibited by blocking IL-6R with neutralizing antibodies ([@B44]). Patients who suffer from primary parathyroidism show elevated IL-6 and markers of increased bone resorption ([@B45]), further demonstrating how this hormone is involved in IL-6-associated bone diseases.

It would be overly simple to say that IL-6 is solely detrimental to bone, as recent *in vivo* work has shown a key role for it in bone repair. Transgenic mice overexpressing IL-6 have demonstrated enhanced bone loss, faulty osteoid ossification, and reduced osteoblast activity ([@B46]), but, other studies have also shown that IL-6 knock-out (KO) mice display abnormalities in bone architecture and delayed fracture healing ([@B47]). These IL-6 KO mice demonstrated delayed mineralization and remodeling of bone, with enhanced levels of collagen and cartilage at early stages of healing and reduced osteoclast number ([@B47]). This demonstrates a necessity for IL-6-induced bone loss in the correct repair of fractures. This is further evidenced in a diabetes-associated fracture model where reduced osteoclastic activity resulted in delayed repair ([@B48]).

IL-6 and Rheumatoid Arthritis (RA)
----------------------------------

RA is a chronic, inflammatory condition prevalent in middle-aged people and is the leading cause of work-associated disability in the United States ([@B49]). Characterized by inflammation of the synovium of multiple joints of the body, sufferers exhibit pain and stiffness in hands, knees, wrists and feet. Progression of the disease results in detrimental damage to the joint and erosion of both the cartilage and bone. RA patients commonly express high levels of IL-6 intracellularly, which has been shown to have negative correlations clinically with bone mass density (BMD) ([@B50]). Increased vascular permeability and extravasation of fluid into synovial regions are key characteristics of RA and induce joint pain. Excess vascularization, a direct effect of IL-6-induced VEGF overexpression, enhances fluid build-up in joints ([@B51]). Antibodies against IL-6R can reduce VEGF expression in RA clinically ([@B51]).

In IL-6 KO mouse models, mice are protected against arthritis and have decreased osteoclast activity and bone loss ([@B52]). In addition, IL-6 neutralizing antibodies have been administered to mice in collagen-induced *in vivo* arthritis models, where they protected the mice from bone lesions and disease progression ([@B53]). Similarly, IL-6R antagonists have been shown to reduce osteoclastogenesis and reduce bone resorption in arthritic mouse models ([@B54]). The sIL-6R has also been shown to be of importance *in vivo*, as co-administration of mice with IL-6 and sIL-6R resulted in restoration of arthritic diseased states in IL-6 KO models ([@B55]). Having said this, some studies using male IL-6 KO mice demonstrated phenotypes of advanced osteoarthritis upon aging, complicating the story ([@B56]). Overall, most findings suggest that IL-6 induces RA initiation and progression ([@B57]).

Currently, targeting IL-6 therapeutically for RA has been successful in the clinic, although the negative side effects from this therapeutic approach should not be minimized. The U.S. Food and Drug Administration declined to approve Johnson & Johnson\'s RA anti-IL-6 drug called sirukumab, saying additional clinical data is needed to further evaluate its safety in September of 2017 ([@B58]). Sirukumab is a chimeric (murine-human) IgG1κ monoclonal antibody (mAb) that binds and neutralizes human IL-6. FDA panelists were concerned about an imbalance in the number of deaths in patients taking sirukumab compared with those taking a placebo, but Johnson & Johnson are continuing further development and testing of the drug ([@B58]). The most common causes of death were major heart problems, infection and cancers ([@B58]). However, Genentech\'s drug known as Actemra® (tocilizumab), the first humanized anti-IL-6 receptor agonist, has been FDA approved since 2010 for RA and was recently approved (November, 2018) as a prefilled autoinjector known as ACTPen^TM^ for RA and patients with giant cell arthritis (GCA), active polyarticular juvenile idiopathic arthritis (PJIA) or active systemic juvenile idiopathic arthritis (SJIA) ([@B59]). Tocilizumab can cause serious side effects however ([@B59]), and hence safer options are still desired for patients with RA and other inflammatory diseases. Still, effects of tocilizumab on bone look promising, as different clinical trials have reported that patients experienced a decrease in osteogenic inhibitor DKK1, CTX-1 bone turnover markers, and in erosions of bone in the hands, and an increase in OPG with bone histology and P1NP bone formation markers in blood ([@B60]--[@B65]).

In May of 2017, Regeneron Pharmaceutical\'s Kevzara® (sarilumab), another IL-6 receptor antagonist, received FDA approval for treatment of adult patients with moderately to severely active RA ([@B66]). Similarly to the IL-6/IL-6R-targeting drugs, sarilumab also increases the risk of serious side effects that may lead to hospitalization or death, largely due to the suppression of the immune system ([@B66]). These therapies would be greatly improved if IL-6 could be targeted in the tissues or areas of interest rather than systemically. Moreover, better success may be achievable using bi-specific antibodies, such as one termed MT-6194 currently in preclinical studies targeting IL-17A and IL-6R ([@B67]). Research into these and other innovative ways to target IL-6 are crucial new directions for the next generation of anti-IL-6/IL-6R therapies, but as many of the current therapies already have FDA approval, despite toxicities, it is unlikely that pharmaceutical industries feel the financial incentive to move in this direction in their Research and Development departments. It may depend on academic scientists, doctors, patients, or companies that do not have a currently FDA approved anti-IL-6 therapeutic, to push for improvements and innovations in targeting IL-6.

IL-6 and Osteoporosis
---------------------

Aging increases the production of inflammatory molecules, including IL-6, which explains some of the increased prevalence of inflammatory disorders (diabetes, lupus, and RA) in aging ([@B68]--[@B70]). Osteoporosis is also common in older and post-menopausal women due to a natural reduction in estrogen levels and high IL-6 levels, adding to increased osteoclastogenesis and pronounced osteopenia ([@B71], [@B72]). Ordinarily, the estrogen isomer 17-β-oestradiol (E2) reduces monocyte secretion of IL-6 and IL-8 ([@B73]), and thus after menopause, these pro-osteoclastic cytokines become more abundant ([@B74]). E2 interacts with the NFκB pathway, which is ordinarily held in an inactive state by coupling with an inhibitor known as IκBα (Figure [2](#F2){ref-type="fig"}). Certain signals result in IκBα becoming phosphorylated, uncoupling from NFκB and releasing it from its inactive state, allowing for signaling of downstream genes ([@B75]). Studies show that E2 promotes IκBα coupling to NFκB, keeping it in an inactivate state ([@B76]). This indicates how a loss in estrogen can result in increased IL-6 and NFκB signaling, and a consequential increase in bone loss and osteoporosis.

![IL-6 signaling in the tumor cell of the bone marrow niche. The bone marrow microenvironment augments MAPK and PI3K/Akt pathways resulting in anti-apoptotic and NF-κB signaling in multiple myeloma cells. Binding of IL-6 to IL-6R and Gp-130 co-receptors induces JAK-2 signaling. This signaling cascade diverges down STAT3/PI3K/Akt pathways and various MAPK pathways, including MEK/ERK. The former is associated with promoting anti-apoptotic proteins: MCL1, BCL-XL, BCL-2 and c-Myc, which contribute to drug resistance. STAT3/PI3K/Akt can also promote NF-κB signaling which results in release of angiogenic and inflammatory molecules, such as IL-6. This can feed into an autocrine positive feedback loop. IκBα can inhibit NFκB through coupling and this interaction can be maintained by certan signals, such as by estradiol. The IL-6 signaling pathway in MM cells is similar to that of bone marrow stromal cells and overall it promotes an inflammatory microenvironment in the bone which results in bone loss, increased tumor burden and disease progression. Bone marrow adipocytes (BMAs) are one cell within the bone microoenvironment thought to feed into this system through secretion of IL-6. This can promote anti-apoptosis and disease progrssion through NF-κB signaling. BMAs, thus, represent an ideal target for MM therapies in order to reduce drug resistance and relapse, instead of targeting the complicated, clonally expanding plasma cell.](fendo-09-00788-g0002){#F2}

Bone loss induced by the E2-NFκB-IL-6 pathways can be reversed by administration of E2 ([@B72]) or anti-IL-6 neutralizing antibody ([@B77]--[@B79]). Clinically, post-menopausal women demonstrate an increased risk of osteoporosis, and patients with certain polymorphisms in the IL-6 promoter show further increases in bone resorption rates and reduction in BMD ([@B80]). This highlights how variation in IL-6 expression within patients can alter the risk of osteoporosis in estrogen-depleted environments. Currently, targeting IL-6 therapeutically for osteoporosis has not been explored, but this is an interesting clinical future direction that holds great potential if the side effects from these types of therapies can be minimized.

IL-6 and Bone-Metastatic Cancer {#s4}
===============================

Paul Ehrlich first proposed the function of the immune system as the first line of defense against cancer in the early twentieth century. Since then, the roles of immune and stromal cells, and their secretory repertoires, have been extensively studied in conjunction with cancer. Inflammation in particular has been shown to be key in promoting cancer proliferation and differentiation, with IL-6 being an integral player ([@B81]). Many cancer types have been shown to be associated with high serum IL-6 including colorectal ([@B82]), breast ([@B83]), and prostate cancer ([@B84]), as well as MM ([@B85]). These cancers induce phenotypic changes in the surrounding stromal cells, creating unique cell types, such as tumor-associated macrophage (TAMs) ([@B86], [@B87]) and cancer-associated fibroblasts (CAFs) ([@B76], [@B77]). These activated stromal cells, along with CD4^+^ T cells and myeloid-derived suppressor cells (MDSCs), are the main sources of IL-6 in most tumor microenvironments, alongside the tumor cells themselves ([@B88]--[@B92]). Consequently, these BMM cells are associated with creating pro-oncogenic environments that promote proliferation and progression of cancer cells by favoring angiogenesis and metastasis, and inhibiting apoptosis ([@B93]--[@B96]). For example, knockdown of IL-6 by RNAi within CAFs can attenuate metastatic phenotypes *in vivo* ([@B94]). It is not surprising that level of IL-6 within the serum of various cancer patients is a key prognostic indicator for their response or disease progression ([@B88]). As a rule, high levels of IL-6 are associated with aggressive forms of cancers ([@B97]--[@B100]) and IL-6 levels can act as independent markers of prognosis in certain cancers ([@B101]). Furthermore, high expression of IL-6 has been more closely linked to recurrent tumors than primary tumors ([@B102]). IL-6 promotes proliferation ([@B103]), facilitates an epithelial-to-mesenchymal transition ([@B94], [@B104]) and enhances angiogenesis via VEGF stimulation ([@B105], [@B106]). Increased IL-6 in cancer cells results in subsequent release of IL-6 by stromal cells, thus feeding into the pro-tumoural feed-forward loop and exacerbating the diseased state ([@B107]--[@B109]).

Chemotherapeutics and ionizing radiation are the most common cancer therapies that work by disrupting DNA and protein synthesis pathways resulting in apoptosis. Yet both are known to stimulate oxidative stress, the NFκB pathway, and consequently IL-6 ([@B110]--[@B114]). IL-6 stimulation then counteracts the chemotherapy effect by promoting anti-apoptotic pathways to cause drug resistance ([@B115]). The anti-myeloma drug bortezomib targets the 26S subunit of the proteasome, the cellular machinery involved in degrading misfolded proteins, and causes an accumulation of unwanted/toxic proteins within cells ([@B116]). This accumulation of proteins is particularly seen in cells that already have dysfunctional or excessive protein-folding processes, such as myeloma cells ([@B117]). Misfolded protein accumulation results in increased ER stress, cell cycle arrest and programmed cell death ([@B118]). However, IL-6 has been shown to induce anti-apoptotic pathways in certain cancers, thus attenuating the efficacy of this drug ([@B119]--[@B121]). Gemcitabine is a nucleoside analog that causes termination of DNA synthesis ([@B122]). Gemcitabine targets fast-replicating cancer cells and resistance to this drug may also be tied to IL-6, as evidenced by a study where gemcitabine-resistance was observed in cancer cells treated with IL-6 and sIL-6R. This was thought to be due to a IL-6-prompted barricade of cells in G0/G1 cell cycle stages, preventing cells from entering the necessary cell-division stages necessary drug-induced replicative-associated destruction ([@B26], [@B123]--[@B125]).

As stated above, IL-6 also plays roles in apoptosis, which occurs due to cellular mishaps as a means to reduce malignancy. Interestingly, IL-6 has been shown to play both pro- and anti-apoptotic roles depending on tumor type. In some p53-wild-type breast and colon cancers, when tumors were treated with kinase inhibitors and general chemotherapies, IL-6 was shown to induce apoptosis via p53 and STAT5, with downstream signaling occurring through BAX \[the reciprocal protein to anti-apoptotic BCL-2 ([@B128])\]. On the other hand, certain cancers, including many bone-metastases, have an opposing phenotype and demonstrate a sustained and even enhanced proliferation due to IL-6 and similar cytokines ([@B113]--[@B115]).

Bone metastatic cancer cells can become dormant within the BMM, thus protecting them from elimination by the immune system ([@B127]). It is common for these tumors to eventually become proliferative and induce osteoclastogenesis through secretion of soluble factors ([@B128], [@B129]). Melanoma cell lines have been shown to home to the bone and induce bone destruction through a TGF-β-IL-11 axis via osteoblasts ([@B130]), whilst other cancers facilitate similar pathways, such as TGF-β-RANKL-mediated destruction ([@B131]). IL-6 and its bone destructive roles can be tied to certain cancers, including MM and neuroblastoma, both of which induce IL-6 secretion from the surrounding stroma resulting in bone loss through the NFκB pathway ([@B132], [@B133]). MM cells derive from the immune plasma cell, home to the BM, cause bone destruction, and eventually become drug resistant. IL-6 plays a role in all these steps, so this review will focus on the effects of IL-6 in MM, as a disease model, from here on.

IL-6 and MM Homing to the Bone Marrow Niche
-------------------------------------------

Chemokine gradients, such as that created by SDF-1, play a large role homing of cells to the BMM. The CXCR4-SDF1 axis is known to promote IL-6 expression in numerous cancers, including MM ([@B3], [@B134]), and other studies have also indicated that IL-6 may promote CXCR7-SDF1 or CXCR4-SDF1 signaling ([@B135]), and as such promote bone-homing ([@B136]). SDF1 is constitutively expressed by stromal cells and osteoblasts in the BMM ([@B127], [@B128]), and attracts CXCR4^+^/CXCR7^+^ haemopoietic or tumor cells to the BMM ([@B137]). B-cells, MM cells, and other bone metastatic cancer cells, including breast and melanoma cells, express CXCR4, which functions in the proliferation and migration of these cells to the SDF1-rich BMM ([@B138]--[@B141]). The CXCR4-SDF1 axis can also promote the expression of molecules that enable adhesion of cells to the endothelial lining of the BM sinus, such as VCAM1 ([@B142]). Additionally, α4β1 integrins can overexpressed due to CXCR4-SDF1 signaling, which can further enhance homing to the BM ([@B142], [@B143]). In contrast, TGF-β1 supresses expression of SDF-1 and has been shown to reduce BM stromal cell (BMSC) migration and adhesion, which could translate to a reduced ability to traffic to the BM ([@B144]). It is unsurprising that a CXCR4 inhibitor has been shown to disrupt MM cell interaction with the BMM and thus increase sensitivity to treatment ([@B145]).

Myeloma cells also commonly express cell surface receptors CCR1 and CCR2 ([@B146], [@B147]), which bind MIP-1α and MCP1-3, respectively. Similar to SDF1, these ligands are expressed highly by BMSCs and promote myeloma cell migration and homing to the BMM ([@B148], [@B149]). All three receptor axes (CCR1, CCR2, CXCR4) are interesting from a clinical point of view as patients with low expression of these receptors have shown poor disease prognosis, associated with high serum β2 microglobulin and C-reactive protein ([@B146]). The former is a molecule secreted by B cells and acts as a marker of disease progression and poor prognosis in MM. The latter is a marker of systemic inflammation and again marks poor clinical prognosis in MM. It is possible that the downregulation of the receptors results in a reduced ability to home to and reside within the BMM and an increase in circulating myeloma cells, which may cause more systemic spreading of the disease. However, this contradicts our typical understanding that tumor cells are more protected in the BM, and thus cause worse outcomes when lodged in the bone rather than when in circulation. Interestingly, IL-6 KO mice are known to express lower levels of IL-2 ([@B150]), a cytokine known to promote CCR1 and CCR2 ([@B151]). Taken together, these data indicate that IL-6 may increase MM bone homing through promoting not only CXCR4 and possibly CCR2/3 signaling.

IL-6--Driven Bone Destruction in MM
-----------------------------------

MM also increases osteoclast number and activity, which leads to hypercalcaemia, renal-insufficiency, anemia, osteopenia and lesions in the bone. The breakdown of bone promotes chronic pain, increases fracture risk, and results in the release of bone-derived growth factors, which feed the tumor cells and promote disease progression ([@B17], [@B18]). This vicious cycle leads to a poor quality of life and ultimately results in prolific dissemination of these plasma cells throughout the body, a fatal condition known as plasma cell leukemia.

A number of factors feed into MM-bone loss including osteocyte-derived sclerostin. In MM patients, elevated circulating sclerostin levels are commonly seen, particularly in advanced stages ([@B152]). Sclerostin has anti-osteoblastic properties and anti-sclerostin therapeutics are currently being investigated for use in MM-associated bone loss pre-clinically ([@B153], [@B154]). Anti-sclerostin antibodies also reduce BM adiposity, and hence more research into their effects on bone or cancer though modulating BM adiposity is warranted ([@B155], [@B156]). DKK1 is another Wnt inhibitor involved in MM-mediated bone loss and disease progression that has been investigated as a target in MM bone loss ([@B157]). DKK1, like sclerostin, inhibits osteoblastogenesis by blocking differentiation of pre-osteoblasts by impeding the WNT signaling cascade ([@B158]). Recently, a bispecific antibody targeting sclerostin and DKK-1 has been shown to promote bone mass accrual and fracture repair in rodents and non-human primates ([@B159]). In addition to simply reducing numbers of mature osteoblasts, DKK1 also increases the number of undifferentiated BMSCs, and these undifferentiated BMSCs secrete higher IL-6 amounts than their differentiated counterparts ([@B160]), thus feeding into the IL-6-bone-destruction pathway described previously. Inhibition of IL-6 from MSC-conditioned media slowed the proliferation of DKK-1 secreting myeloma cells treated with this media, suggesting that in the myeloma environment, IL-6 increases bone resorption through promoting proliferation of DKK-1-secreting myeloma cells ([@B160]). However, in other contexts, a negative correlation between IL-6 and DKK1 was observed, implying that more research into the role of IL-6 in bone destruction would be useful ([@B161]).

IL-6 mediated bone loss also occurs due to direct expression and release of IL-6 by MM cells and consequential osteoclast activation. The mechanism of IL-6-mediated osteoclastogenesis is thought to be due primarily to activation of the JAK2/STAT3 axis, resulting in upregulation of RANKL molecules ([@B24]) (see Figure [2](#F2){ref-type="fig"}). This overthrows the fine balance between osteoclastic RANKL molecules and their inhibitor, OPG, pushing the equilibrium in favor of bone loss ([@B162]). In addition, IL-6 may also make preosteoclasts more sensitive to RANKL stimulation, presumably due to an IL-6-mediated upregulation of RANK receptors, which was previously shown in Paget\'s disease ([@B163]). *In vivo* studies have confirmed IL-6 mediated bone loss in both trabecular and endochondral bone; this bone loss is enhanced in the presence of MM cells and is associated with increased osteoclast differentiation ([@B164]). This finding is being investigated in phase II clinical trials, which are currently examining the efficacy of anti-IL-6 treatment on MM bone-loss (NCT01484275).

IL-6 and MM Disease Progression
-------------------------------

MM begins as a condition known as monoclonal gammopathy of undetermined significance (MGUS), an asymptomatic stage where levels of immunoglobulin in the blood and risk of fracture are elevated. Blood serum IL-6 levels correspond to prognosis and progression of MM ([@B85]); prognosis is worse when levels exceed 7 pg/ml, with an average survival of 2.7 months compared to 53.7 months in those with lower levels ([@B85]). IL-6/STAT3 pathways are known to promote angiogenesis via enhancement of VEGF in MM ([@B165]). Osteoclasts are also known to secrete pro-angiogenic molecules, and thus in MM when both osteoclast number and activity is enhanced, there is also an increase in the development of vasculature ([@B166]). IL-6/STAT3 signaling not only promotes the creation of these new endothelial cells, but also stimulates Ras, Akt and MAPK pathways which promotes the survival of said MM cells ([@B167]).

IL-6--Mediated Drug Resistance and Survival in MM
-------------------------------------------------

Apoptosis involves the activation of caspase enzymes in a cascade ending in the activation and release of apoptosis-inducing factors from mitochondria. Apoptosis-inducing agents cause DNA fragmentation and chromatin condensation, which ultimately induces cell death ([@B168]). IL-6 promotes JAK/STAT3 and consequently PI3K/Akt and MEK/MAPK ([@B169]), (Figure [2](#F2){ref-type="fig"}); these pathways are known to upregulate anti-apoptosis proteins Mcl-1, Bcl-XL and c-Myc in primary MM cells, resulting in cell survival and chemotherapy resistance ([@B170], [@B171]). A number of antibodies have been investigated to neutralize IL-6, but little success has occurred clinically ([@B172], [@B173]). However, evidence indicates that indirect targeting of downstream anti-apoptosis mediators can help reverse the effects of IL-6. *In vitro*, anti-sense targeting strategies against MCL-1 sensitized MM cells to drugs by inhibiting these anti-apoptotic pathways ([@B174]). In addition, IL-6-mediated resistance was reversed by targeting CDC34 ([@B175]). This molecule is an ubiquitin-conjugating enzyme involved in proteasomal degradation. It has been tied to ubiquitination and degradation of IκBα, the NFκB inhibitor, and thus promotes drug resistance via NFκB signaling. Targeting other molecules within the JAK/STAT3 cascade also appears to aid in resistance reversal, as the Akt inhibitor, MK2206, has also been found to help overcome bortezomib resistance in MM cells induced by co-culturing with IL-6 or MSCs ([@B176]). \[For more on IL-6 and proteasome inhibitor resistance in MM, we refer the reader to our recent review may ([@B123])\].

IL-6 may also cause drug resistance through epigenetic modulation proteins. IL-6 signals via STAT3 and enhances DNA methyltransferase 1, which promotes the methylation and thus deactivation of P53, facilitating cells to avoid cell cycle checkpoint destruction ([@B177]). This could clearly have unfavorable effects in MM, promoting drug resistance and/or disease progression. Initial studies into use of general histone deacetylase (HDAC) inhibitors were unfavorable ([@B178]), however, subsequent use of selective HDAC inhibitors, such as chidamide, have shown anti-MM and bone protective effect, showing synergistic effects with other therapies such as dexamethasone, carfilzomib and pomalidomide ([@B179]).

Bone Marrow Adipocyte (BMA)-Derived IL-6 Contribution to MM Progression
-----------------------------------------------------------------------

Obesity is an increasingly common condition which increases one\'s risk of cardiovascular disease, diabetes, certain cancers, and many other diseases. One link to cancer is due to the increased inflammatory state which occurs due to obesity ([@B180]). The excess storage of lipids within adipose tissues causes the release of inflammatory molecules, TNF-α and IL-6, and suppression of anti-inflammatory adiponectin ([@B181]). This creates a microenvironment of high oxidative stress and inflammation and results in damage to tissues, increasing one\'s risk of oncogenic mutations and tumorigenesis ([@B180]). Increased fat intake, which typically causes obesity over time, is linked to higher levels of BM adiposity in rodents ([@B182]); recently, BM adipocytes (BMAs) have been shown to play significant roles in MM drug resistance and disease progression ([@B183]), possibly through the secretion of soluble factors, such as IL-6 ([@B184]). BMAs have such a profound effect on MM that, clinically, obese and older populations, both of whom suffer from enhanced systemic inflammation and increased BMA levels, demonstrate higher risk of developing MM than other groups of people ([@B185]).

BMAs may contribute to disease progression in numerous ways. *In vitro* work has demonstrated an ability of BMAs extracted from MM patient femurs to support MM cell growth and protect them from chemotherapy-induced apoptosis ([@B186]). In addition, MM is known to increase expression of PGC-1α within BMAs, resulting in VEGF and GLUT-4 expression ([@B187]), which increases proliferation, angiogenesis and metastasis, as described above. BMAs have also been shown to increase expression of autophagic proteins within MM cells, which can promote drug resistance ([@B186]). Finally, BMA-derived IL-6 has been hypothesized to contribute to chemotherapy resistance due to an upregulation of anti-apoptotic proteins and inhibition of cell checkpoint proteins (Figure [2](#F2){ref-type="fig"}). The latter pathway remains unverified, yet studies are currently underway to investigate this further. If true, IL-6 and its downstream signaling molecules represent good targets for possible re-sensitization of MM cells in refractory disease. Investigation into the blockade of anti-apoptotic pathways downstream of IL-6 and other IL-6 mediated pathways is warranted. In addition, efforts should be made to find therapeutics that target BMAs specifically, and to investigate the secretory repertoires of all BMM cells to better understand and manipulate the microenvironment into one of anti-tumorigenicity.

Clinically Targeting IL-6 in Cancer
-----------------------------------

Despite extensive pre-clinical *in vitro* and *in vivo* support for the role of IL-6 in MM and other osteolytic bone cancers, clinical translation results have been dismal. Clinical trial results with siltuximab, formerly CNTO 328, in MM have been disheartening and no clinical trials in other bone cancers have been initiated as of yet. As presented in an abstract for the American Society of Hematology (ASH), 2017 annual meeting, IL-6 blockade did not add benefit to chemotherapy in a phase 2, randomized, double-blind, placebo-controlled multicenter study in patients with high-risk smoldering MM ([@B188]). A clinical trial examining if siltuximab can decrease symptom burden after autologous stem cell transplantation for patients with MM or AL amyloidosis is currently underway (ClinicalTrials.gov Identifier: NCT03315026). No data on MM and siltuximab was presented at the ASH 2018 conference. A study of CNTO 328 in Japan from 2011 to 2014 in relapsed or refractory MM patients was halted due to safety concerns (ClinicalTrials.gov Identifier: NCT01309412). An open-label, phase I trial of CTNO with lenalidomide, bortezomib and dexamethasone (RVD) was performed (ClinicalTrials.gov Identifier: NCT01531998), however the efficacy data were limited by the small number of patients since the trial was halted and did not proceed to phase II. The abandonment of the phase II trial was due to the negative outcomes from another phase II study of bortezomib-melphalan-prednisone (VMP) vs. VMP+siltuximab, which demonstrated no significant improvement in progression-free survival. After this finding, further development of siltuximab in symptomatic myeloma was halted by the sponsor ([@B189]). Trials have also been initiated examining the safety and efficacy of siltuximab in metastatic, hormone-refractory prostate cancer, renal and other solid tumors (ovarian, pancreatic, colorectal, and others), and the field is currently waiting to see the results of these trials ([@B190]).

Tocilizumab, a humanized anti-IL-6R mAb, is currently the subject of investigation in many clinical cancer trials. Current clinical trials are ongoing for metastatic HER2-positive breast cancer resistant to trastuzumab, lymphoblastic leukemia, pancreatic cancer, myeloid leukemia, B-cell chronic lymphocytic leukemia, non-Hodgkin\'s lymphoma, B-cell lymphoma, and diffuse large B-cell lymphoma (ClinicalTrials.gov). Trials in myeloma were terminated due to low accrual rate (ClinicalTrials.gov Identifier: NCT02057770). In Europe, there is currently a clinical trial to explore the use of tocilizumab in fibrous dysplasia of bone (FD), a rare, painful bone disease affecting one or several bones ([@B191]). If promising data result, more clinical trials may arise studying the drug for bone pain relief applications.

Unfortunately, overall, large randomized trials show no efficacy of IL-6 inhibitors in various cancers, particularly myeloma. These results are despite a full inhibition of C-reactive protein (CRP) production in treated patients, the numerous preclinical studies showing an involvement of IL-6 in these diseases, and initial short-term treatments demonstrating a dramatic inhibition of cancer cell proliferation *in vivo* ([@B192]). Similarly, a meta-review of 48 clinical studies concluded that inhibition of IL-6 has unknown and unproven effects on decreasing GI (gastric, pancreatic, colorectal, bile duct and gall bladder) cancer syndromes or improving quality of life ([@B191]). A likely explanation for this lack of efficacy is the plasticity of cancer cells and their ability to clonally evolve and develop subclones that are less dependent on IL-6. Moreover, many therapies targeting tumor cells already decrease IL-6 or pathways downstream of IL-6, so that no additive or synergistic effect is derived from the anti-IL-6 therapy. Still, anti-IL-6 therapeutics are able to neutralize IL-6 production *in vivo* and are safe and useful in inflammatory diseases and Castleman disease. Their application may hold promise in treatment of bone-resident cancers if more developed (e.g., bi-specific mAbs against tumor cells and IL-6, or against RANKL and IL-6) therapies can be developed to increase their efficacy. Moreover, getting the treatment more specifically to the cancer may allow for higher doses and less off-target effects, and thus better outcomes, and more research into tumor-homing drug delivery or targeted nanomedicine technology may accelerate this process. As we understand more about the role of the immune system in cancer and the ability for tumor cells to block the immune response, researchers and clinicians may be able to design anti-IL-6 clinical trials using patient populations that are identified to have a positive response to these therapies. Similarly, a better understanding of the full activity of anti-IL-6 therapy will mean that different combination regimens or dosing strategies may be designed to be optimal for different patient subgroups.

Conclusions {#s5}
===========

IL-6 is a pro-inflammatory cytokine that promotes NF-κB, MAPK and PI3K/Akt signaling. Together these pathways promote anti-apoptosis signaling and drug resistance in cancer cells, in addition to further inflammatory signaling. The latter contributes to bone destruction and osteopenia, which promotes homing of metastatic cancers to the bone marrow niche. Bone marrow adipocytes, as well as mesenchymal stromal cells, may be a source of IL-6 or other factors, that contribute to chemotherapy resistance in the bone microenvironment. Targeting of these adipocytes, or their secreted factors, may help alleviate refractory disease.

Because MM demonstrates such genetic heterogeneity and high levels of refractory disease, targeting the BMM, along with the tumor cell directly, is an ideal plan of attack. The IL-6 signaling pathway in MM cells promotes an inflammatory bone microenvironment that results in osteopenia, increased tumor burden and disease progression. Bone marrow adipocytes are one cell type within the bone microoenvironment thought to feed into this system through secretion of IL-6 and other adipokines. Thus, bone marrow adipocytes represent an ideal target for MM therapies in order to reduce drug resistance and relapse, instead of targeting the complicated, clonally expanding plasma cells. The more we learn, the better we can target such pathways and not only improve quality of life for patients, but hopefully extend that lifetime as well. As this dream has not become realized in the clinic yet, more efforts on understanding and maximizing the targeting of IL-6 and its downstream pathways may be necessary. Moreover, building mouse cancer models, or tissue-engineered 3D models, that more accurately model the effects of targeting IL-6 in the human should lead to better clinical results in the future and avoid the pitfalls of wasted time and money on unsuccessful clinical trials.
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